How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice-Reference-Cited by-同舟云学术

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice

Published:2016-07 Issue:4 Volume:82 Page:965-973
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Tafuri Giovanni¹²,Pagnini Margherita¹,Moseley Jane¹,Massari Marco²,Petavy Frank¹,Behring Antje³,Catalan Arantxa⁴,Gajraj Elangovan⁵,Hedberg Niklas⁶,Obach Mercè⁴,Osipenko Leeza⁵,Russo Pierluigi²,Van De Casteele Marc⁷,Zebedin Eva‐Maria⁸,Rasi Guido¹,Vamvakas Spiros¹

Affiliation:

1. European Medicines Agency (EMA) 30 Churchill Place London E14 5EU UK

2. Italian Medicines Agency (AIFA) via del Tritone 181 ‐ 00187 Rome Italy

3. German Federal Joint Committee (G‐BA) Wegelystr. 8 D‐10623 Berlin Germany

4. Catalan Agency for Health Quality and Assessment (AQuAS) Carrer de Roc Boronat 81‐95 08005 Barcelona Spain

5. National Institute for Health and Care Excellence (NICE) 10 Spring Gardens London SW1A 2BU United Kingdom

6. Dental and Pharmaceutical Benefits Agency (TLV) Fleminggatan 7 112 26 Stockholm Sweden

7. National Institute for Sickness and Invalidity Insurance (INAMI) Avenue de Tervueren 211 1150 Bruxelles Belgium

8. Main Association of Austrian Social Security Institutions (HVB) Kundmanngasse 21 A‐1031 Vienna Austria

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13023

Reference20 articles.

1. Key principles for the improved conduct of health technology assessments for resource allocation decisions

2. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers

3. Health economics and outcomes research within drug development

4. The role of health technology assessment bodies in shaping drug development

5. Pharmaceutical industry: a strategic sector for the European economy. European Commission Brussels 1.8.2014 SWD(2014) 216 final/2. Available athttp://ec.europa.eu/growth/sectors/healthcare/index_en.htm(last accessed March 2016)

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments;Drug Safety;2023-12-19

2. Real-world evidence for regulatory decision-making: updated guidance from around the world;Frontiers in Medicine;2023-10-30

3. Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?;Expert Review of Pharmacoeconomics & Outcomes Research;2023-09-28

4. Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts;BMJ Open;2023-08

5. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement;International Journal of Technology Assessment in Health Care;2023